Filana Therapeutics, Inc. Total Assets
Filana Therapeutics, Inc. total assets. Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) holds total assets worth $103.90 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Filana Therapeutics, Inc. (FLNA) total market value for the company's overall valuation and market capitalisation.
Total Assets of Filana Therapeutics, Inc. (2022–2025)
Total assets of Filana Therapeutics, Inc. from 2022 to 2025. This chart illustrates how Filana Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See FLNA share price today for real-time trading data and today's change.
Filana Therapeutics, Inc. - Asset Composition Analysis
Filana Therapeutics, Inc. Total Assets Breakdown (December 2025)
Filana Therapeutics, Inc. total assets breakdown as of December 2025. Filana Therapeutics, Inc.'s total assets of $103.90 Million consist of 82.6% current assets and 17.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.7% |
| Accounts Receivable | $120.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Filana Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore FLNA net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Filana Therapeutics, Inc.'s current assets represent 82.6% of total assets in 2025, a decrease from 90.0% in 2022.
- Cash Position: Cash and equivalents constituted 80.7% of total assets in 2025, down from 85.6% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Filana Therapeutics, Inc. Competitors by Total Assets
Key competitors of Filana Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Filana Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.08 | 2.43 | 3.55 |
| Quick Ratio | 2.08 | 2.43 | 3.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $43.56 Million | $67.49 Million | $145.51 Million |
Filana Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Filana Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.78 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | -24.9% |
| Total Assets | $118.36 Million |
| Market Capitalization | $28.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Filana Therapeutics, Inc.'s assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Filana Therapeutics, Inc.'s assets decreased by 24.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual total assets of Filana Therapeutics, Inc. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $118.36 Million | -24.87% |
| 2024-12-31 | $157.53 Million | +3.87% |
| 2023-12-31 | $151.66 Million | -35.42% |
| 2022-12-31 | $234.83 Million | -- |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more